Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3435151 in Advanced Solid Tumors
NCT04099277Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2019
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of LY3435151 in solid tumor, triple-negative breast cancer (TNBC), gastric adenocarcinoma and 6 more (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Dose-Limiting Toxicities. Started Oct 2019; status: terminated.
02
Drugs
LY3435151
03
Conditions
solid tumortriple-negative breast cancer (TNBC)gastric adenocarcinomahead and neck squamous cell carcinoma (HNSCC)cervical carcinoma
Beyond the preview
Go deeper on NCT04099277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04099277.